-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WVMIOCcqDOT7yK3ZH+tQWU7AjtwSGj/TyZ6BtdYPXRcnMDLWWSw4oGqFwWyGX/Nm VVoUn4hNN45coQOoSnuQrA== 0001015402-02-000343.txt : 20020414 0001015402-02-000343.hdr.sgml : 20020414 ACCESSION NUMBER: 0001015402-02-000343 CONFORMED SUBMISSION TYPE: S-3 PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20020208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENUS INC CENTRAL INDEX KEY: 0000837913 STANDARD INDUSTRIAL CLASSIFICATION: SPECIAL INDUSTRY MACHINERY, NEC [3559] IRS NUMBER: 942790804 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-82354 FILM NUMBER: 02530413 BUSINESS ADDRESS: STREET 1: 1139 KARLSTAD DRIVE CITY: SUNNYVALE STATE: CA ZIP: 94089-2117 BUSINESS PHONE: 4087477120 MAIL ADDRESS: STREET 1: 1139 KARLSTAD DRIVE CITY: SUNNYVALE STATE: CA ZIP: 94089-2117 S-3 1 doc1.txt As filed with the Securities and Exchange Commission on February 7, 2002 Registration No. 333-______ ================================================================================ SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ------------------------ GENUS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) ------------------------ CALIFORNIA 94-2790804 (STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER) 1139 KARLSTAD DRIVE SUNNYVALE, CA 94089 (408) 747-7120 (ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES) ------------------------ WILLIAM W.R. ELDER PRESIDENT AND CHIEF EXECUTIVE OFFICER GENUS, INC. 1139 KARLSTAD DRIVE SUNNYVALE, CA 94089 (408) 747-7120 (NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF AGENT FOR SERVICE) ------------------------ Copies to: MARK CASILLAS ESQ. WILLIAM GRAVES, ESQ. WILSON SONSINI GOODRICH & ROSATI PROFESSIONAL CORPORATION 650 PAGE MILL ROAD PALO ALTO, CA 94304 (650) 493-9300 ------------------------ APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: AS soon as practicable after the effective date of this Registration Statement. If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. [ ] If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. [X] If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ] If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ] If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. [ ]
CALCULATION OF REGISTRATION FEE =================================================================================================================== TITLE OF EACH CLASS OF AMOUNT TO BE PROPOSED MAXIMUM PROPOSED MAXIMUM AMOUNT OF SECURITIES TO BE REGISTERED REGISTERED OFFERING PRICE PER SHARE AGGREGATE OFFERING PRICE REGISTRATION FEE - ------------------------------------------------------------------------------------------------------------------- Common Stock, no par value. 3,871,330 $ 2.41 (1) $ 9,329,905.30 $ 858.35 =================================================================================================================== Common stock issuable upon. exercise of Warrants 580,696 $ 3.23 (2) $ 1,875,648.08 $ 172.56 =================================================================================================================== TOTAL REGISTRATION FEES: $ 1,030.91 =================================================================================================================== (1) Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rule 457(c). Based on the average of the high and low prices of the common stock on February 5, 2002. (2) The Proposed Maximum Offering Price Per Share was determined in accordance with Rule 457(g) under the Securities Act of 1933, as amended, under which rule the per share price is estimated by reference to the exercise price of the securities, which is $3.23
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A), MAY DETERMINE. ================================================================================ PROSPECTUS 3,871,330 Shares GENUS, INC. Common Stock --------------------- This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission relating to the public offering of securities by the shareholders listed herein. The sale of these securities is not being underwritten. The selling security holders may sell the common stock from time to time in the over-the-counter market through the Nasdaq Stock Market, in privately negotiated transactions, through the writing of options on the shares, or through a combination of such methods of sale, at fixed prices that may be changed, at market prices prevailing at the time of sale, at prices relating to such prevailing market prices or at negotiated prices. We will not receive any of the proceeds from the sale of the shares by the selling security holders. However, to the extent the warrants are exercised through payment of the purchase price in cash, rather than a cashless exercise, we will receive the proceeds from such exercise. Our common stock is traded on the Nasdaq National Market under the symbol "GGNS." On January 31, 2002, the average of the high and low sale prices of one share of our stock on Nasdaq was $2.57. THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK. SEE "RISK FACTORS," COMMENCING ON PAGE 2. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. The date of this prospectus is February 7, 2002. TABLE OF CONTENTS Page ---- Prospectus Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Forward-Looking Statements . . . . . . . . . . . . . . . . . . . . . . . . 11 Proceeds. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Selling Security Holders. . . . . . . . . . . . . . . . . . . . . . . . . 12 Description of Equity Securities . . . . . . . . . . . . . . . . . . . . 16 Plan of Distribution. . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Legal Matters. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Experts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Where You Can Find More Information. . . . . . . . . . . . . . . . . . 18 Information Incorporated by Reference. . . . . . . . . . . . . . . . . . 19 We have not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus. The selling stockholders are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of common stock. Our executive offices are located at 1139 Karlstad Drive, Sunnyvale, California 94089, our telephone number is (408) 747-7120 and our internet address is www.genus.com. The information on our internet website is not incorporated by reference in this prospectus. PROSPECTUS SUMMARY This prospectus relates to resales of up to 3,871,330 shares of our issued and outstanding common stock, and 580,696 additional shares of common stock issuable upon exercise of warrants by shareholders listed under "Selling Securities Holders." We sold these securities in a private placement on January 25, 2002. This summary does not contain all of the information that you should consider before investing in our common stock. You should read the entire prospectus carefully, especially the risks discussed under "Risk Factors" on page 2, and the "Information Incorporated by Reference" on page 19. GENUS, INC. Genus, Inc. supplies advanced manufacturing systems for the worldwide semiconductor industry and for related non-semiconductor industries. Semiconductor manufacturers use our equipment and process technology to produce integrated circuits, commonly called memory and logic chips, that are incorporated into a variety of products, including personal computers, communications equipment and consumer electronics. We pioneered the development of chemical vapor deposition for tungsten silicide thin films. The chemical vapor deposition process deposits a thin film of tungsten silicide or other materials in critical stages during the manufacture of integrated circuits. We are also one of the leaders in the commercialization of atomic layer deposition technology. This process enables a semiconductor manufacturer to deposit a layer of film that is one molecule thick, and repeat this process until the desired film thickness is achieved. Atomic layer deposition produces an extremely consistent and uniform film, which is required as the semiconductor industry migrates to feature sizes of 0.13 microns and smaller. The semiconductor industry currently manufactures integrated circuits, or chips, with feature sizes of 0.15 microns and larger in width. However, the industry requires feature sizes of 0.13 microns and smaller for components such as gates, capacitors and interconnect materials and there are challenges associated with implementing the smaller features into volume production. These scaling challenges have been labeled as "red zones" by the International Technology Roadmap for Semiconductors because the industry has previously lacked workable solutions to further reduce feature sizes and simultaneously improve performance. The Semiconductor Roadmap strategically identifies red zones so that suppliers can respond with advanced technology. We have responded to red zones related to scaling challenges in the manufacture of chips with our atomic layer technology. The process of depositing only one molecule at a time makes the atomic level deposition process slower than current methods such as chemical vapor deposition. Smaller feature sizes partially compensate for the slow-down in the production process, however, since smaller chips require films that are much thinner than the ones currently being produced. These thinner films may also be more difficult to etch than current generation films, and the number of companies offering this type of etching equipment is currently limited due to the small size of the market. We are one of the first two companies to supply systems commercially in this emerging market. We recently demonstrated our atomic layer deposition tool under continuous operating conditions and for 2000 wafers. These results were presented at the American Vacuum Society Science and Technology Conference on atomic layer deposition in Monterey in May 2001. In comparison to our demonstration of 2000 wafers, the nearest competitor has only demonstrated 500 wafers and has only reported data on 50 wafers. 1 We have applied for twelve patents in this emerging technology. So far the U.S. Patent and Trademark Office have issued three patents to us in atomic layer deposition technology. Our remaining nine applications are still under review at this time. While atomic layer technology does not generate the majority of our current revenues, we expect it to become the major source of our revenues in the near future. Genus intends to focus on atomic layer deposition technology in building our future. The emerging atomic layer deposition segment of the semiconductor industry is expected to grow from approximately $35 million in 2001 to over $1 billion by 2006, due to the industry's demand for smaller chips. The advanced nature of our atomic layer technology enables the first tier semiconductor companies to manufacture smaller chips for use in advanced and upcoming, or next-generation, applications. Our systems have already been accepted by three of the top ten chip manufacturers in that industry. Our current production platform is used for both the development and production phases of new thin films in integrated circuit manufacturing. Our Lynx series enables both 200 millimeter and 300 millimeter production and provides manufacturers with high reliability and low cost of ownership across a wide range of applications. Our modular design allows manufacturers to easily add capacity and service the manufacturing systems. Our systems operate on standardized software that supports a wide range of thin film deposition processes. The patented process chamber in our Lynx product family permits the configuration of chemical vapor deposition, plasma enhanced deposition, metal organic deposition and atomic layer deposition with minimal adjustment. Our global customer base consists of semiconductor and non-semiconductor manufacturers in the United States, Europe and Asia. Three of our current customers rank among the top ten semiconductor companies in the world, and include Infineon Technologies, Micron Technology, Inc., and Samsung Electronics Company, Ltd. Additionally, Read-Rite, a leading data storage company, uses our atomic layer deposition tools for non-semiconductor applications. 2 RISK FACTORS You should carefully consider the following risks before making an investment decision in our common stock. The risks described below are not the only ones that we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. Our business, operating results or financial condition could be harmed by and the trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment. You should also refer to the other information included in this prospectus and the other information, our financial statements and the related notes incorporated by reference into this prospectus before you decide to purchase shares of our common stock. WE HAVE EXPERIENCED LOSSES OVER THE LAST FEW YEARS AND WE MAY NOT BE ABLE TO ACHIEVE OR SUSTAIN PROFITABILITY We have experienced losses of $9.6 million, $1.6 million and $29.5 million for 2000, 1999 and 1998, respectively. We may not be able to attain or sustain consistent future revenue growth on a quarterly or annual basis, or achieve and maintain consistent profitability on a quarterly or annual basis. SUBSTANTIALLY ALL OF OUR NET SALES COME FROM A SMALL NUMBER OF LARGE CUSTOMERS Historically, we have relied on a small number of customers for a substantial portion of our net sales. For example, Samsung Electronics Company, Ltd. and Micron Technology, Inc. accounted for 91% and 5% of our net sales in 2000. In the first nine months of 2001, Samsung Electronics Company, Ltd., Read-Rite and Infineon Technologies accounted for approximately 72 percent, 8 percent and 6 percent, respectively, of our net sales. Samsung Electronics and Readrite represented approximately 34 percent of accounts receivables at September 30, 2001. The semiconductor manufacturing industry generally consists of a limited number of larger companies. Consequently, we expect that a significant portion of our future product sales will continue to be concentrated within a limited number of customers, even though we are making progress in reducing the concentration of our reliance on customers through our strategy of product and customer diversification. None of our customers has entered into a long-term agreement with us requiring them to purchase our products. In addition, sales to these customers may decrease in the future when they complete their current semiconductor equipment purchasing requirements. If any of our customers were to encounter financial difficulties or become unable to continue to do business with us at or near current levels, our business, results of operations and financial condition would be materially harmed. Customers may delay or cancel orders or may stop doing business with us for a number of reasons including: - customer departures from historical buying patterns; - general market conditions; - economic conditions; or - competitive conditions in the semiconductor industry or in the industries that manufacture products utilizing integrated circuits. 3 OUR QUARTERLY FINANCIAL RESULTS FLUCTUATE SIGNIFICANTLY AND MAY FALL SHORT OF ANTICIPATED LEVELS, WHICH COULD CAUSE OUR STOCK PRICE TO DECLINE Our net sales and operating results may fluctuate significantly from quarter to quarter. For example, in the year 2000, our quarterly revenues ranged from $3.8 million to $15.7 million with the bottom line ranging from a loss of $10 million to a profit of $1.6 million. We derive our revenue primarily from the sale of a relatively small number of high-priced systems, many of which may be ordered and shipped during the same quarter. Our results of operations for a particular quarter could be materially adversely affected if anticipated orders, for even a small number of systems, were not received in time to enable shipment during the quarter, anticipated shipments were delayed or canceled by one or more customers or shipments were delayed due to manufacturing difficulties. At our current revenue level, each sale, or failure to make a sale, could have a material effect on us. Our lengthy sales cycle, coupled with our customers' competing capital budget considerations, makes the timing of customer orders uneven and difficult to predict. Our backlog at the beginning of a quarter typically does not include all orders required to achieve our sales objectives for that quarter. As a result, our net sales and operating results for a quarter depend on us shipping orders as scheduled during that quarter as well as obtaining new orders for systems to be shipped in that same quarter. Any delay in scheduled shipments or in shipments from new orders would materially harm our operating results for that quarter, which could cause our stock price to decline. WE ARE SUBJECT TO RISKS BEYOND OUR CONTROL OR INFLUENCE AND ARE HIGHLY DEPENDENT ON OUR INTERNATIONAL SALES, PARTICULARLY SALES IN ASIAN COUNTRIES Export sales accounted for approximately 98%, 86% and 56% of our total net sales in 2000, 1999 and 1998, respectively, and accounted for 92% of our total net sales during the first nine months of 2001. Net sales to our South Korean-based customers accounted for approximately 92%, 84% and 30% of total net sales, respectively and accounted for 72% of our total net sales in the first nine months of 2001. We anticipate that international sales, including sales to South Korea, will continue to account for a significant portion of our net sales. As a result, a significant portion of our net sales will be subject to risks, including: - unexpected changes in law or regulatory requirements; - exchange rate volatility; - tariffs and other barriers; - political and economic instability; - difficulties in accounts receivable collection; - extended payment terms; - difficulties in managing distributors or representatives; - difficulties in staffing our subsidiaries; 4 - difficulties in managing foreign subsidiary operations; and - potentially adverse tax consequences. Our foreign sales are primarily denominated in U.S. dollars and we do not engage in hedging transactions. As a result, our foreign sales are subject to the risks associated with unexpected changes in exchange rates, which could affect the price of our products. In the past, turmoil in the Asian financial markets resulted in dramatic currency devaluations, stock market declines, restriction of available credit and general financial weakness. For example, prices fell dramatically in 1998 because integrated circuit manufacturers sold dynamic random access memory chips, called DRAMs, at less than cost in order to generate cash. The cash shortfall caused Asian semiconductor companies to defer or cancel investments in new production facilities, thereby reducing our anticipated sales of our semiconductor manufacturing equipment in Asia in 1998. Also during this time, the value of the won, the currency of South Korea, declined significantly against the U.S. dollar. As a result, purchases of U.S. manufactured products became very costly. Since most of our sales were made to South Korean customers, these circumstances adversely impacted our customers' ability to invest in new facilities and equipment that reduced our shipments and profitability in 1998. Wherever currency devaluations occur abroad, our goods become more expensive for our customers in that region. Difficult economic conditions may limit capital spending by our customers. These circumstances may also affect the ability of our customers to meet their payment obligations, resulting in the cancellations or deferrals of existing orders and the limitation of additional orders. OUR SALES REFLECT THE CYCLICALITY OF THE SEMICONDUCTOR INDUSTRY, WHICH COULD CAUSE OUR OPERATING RESULTS TO FLUCTUATE SIGNIFICANTLY AND COULD CAUSE US TO FAIL TO ACHIEVE ANTICIPATED SALES Our business depends upon the capital expenditures of semiconductor manufacturers, which in turn depend on the current and anticipated market demand for integrated circuits and products utilizing integrated circuits. Although we are marketing our atomic layer deposition technology to non-semiconductor markets such as markets in magnetic thin film heads, flat panel displays, microelectromechanical systems and inkjet printers, we are still dependent on the semiconductor market. The semiconductor industry is cyclical and experiences periodic downturns both of which reduce the semiconductor industry's demand for semiconductor manufacturing capital equipment. Semiconductor industry downturns have significantly decreased our revenues, operating margins and results of operations in the past. During the industry downturn in 1998, several of our customers delayed or cancelled investments in new manufacturing facilities and equipment due to declining DRAM prices, the Asian economic downturn, and general softening of the semiconductor market. This caused our sales in 1998 to be significantly lower than in the prior three years. After the dramatic industry boom for semiconductor equipment that peaked early in the year 2000, another cyclical downturn is presently occurring. Industry reports anticipate a fall of 35% in 2001 compared to 2000. This sharp and severe industry downturn is the largest in the industry's history and it is occurring with a slowdown of the U.S. economy overall. Almost all previous downturns have been solely due to pricing declines. The current downturn in the industry marks a corresponding decline in unit production. Genus recently reported a loss for our third quarter 2001 financial results. There is a risk that our revenues and operating results will continue to be further impacted by the continued downturn in the semiconductor industry and global economy. 5 OUR FUTURE GROWTH IS DEPENDENT ON ACCEPTANCE OF NEW THIN FILMS AND MARKET ACCEPTANCE OF OUR SYSTEMS RELATING TO THOSE THIN FILMS We believe that our future growth will depend in large part upon the acceptance of our new thin films and processes, especially our atomic layer deposition technology. As a result, we expect to continue to invest in research and development in these new thin films and the systems that use these films. There can be no assurance that the market will accept our new products or that we will be able to develop and introduce new products or enhancements to our existing products and processes in a timely manner to satisfy customer needs or achieve market acceptance. The failure to do so could harm our business, financial condition and results of operations. We must manage product transitions successfully, as introductions of new products could harm sales of existing products. We derive our revenue primarily from the sale of equipment used to chemically deposit tungsten silicide in the manufacture of memory chips. We estimate that the life cycle for these tungsten silicide deposition systems is three-to-five years. There is a risk that future technologies, processes or product developments may render our product offerings obsolete and we may not be able to develop and introduce new products or enhancements to our existing products in a timely manner. WE MAY NOT BE ABLE TO CONTINUE TO SUCCESSFULLY COMPETE IN THE HIGHLY COMPETITIVE SEMICONDUCTOR INDUSTRY AGAINST COMPETITORS WITH GREATER RESOURCES The semiconductor manufacturing capital equipment industry is highly competitive. We face substantial competition throughout the world. We believe that to remain competitive, we will require significant financial resources in order to develop new products, offer a broader range of products, establish and maintain customer service centers and invest in research and development. Many of our existing and potential competitors have substantially greater financial resources, more extensive engineering, manufacturing, marketing, customer service capabilities and greater name recognition. We expect our competitors to continue to improve the design and performance of their current products and processes and to introduce new products and processes with improved price and performance characteristics. If our competitors enter into strategic relationships with leading semiconductor manufacturers covering thin film products similar to those sold by us, it would materially adversely affect our ability to sell our products to such manufacturers. In addition, to expand our sales we must often replace the systems of our competitors or sell new systems to customers of our competitors. Our competitors may develop new or enhanced competitive products that will offer price or performance features that are superior to our systems. Our competitors may also be able to respond more quickly to new or emerging technologies and changes in customer requirements, or to devote greater resources to the development, promotion and sale of their product lines. We may not be able to maintain or expand our sales if our resources do not allow us to respond effectively to such competitive forces. WE MAY NOT ACHIEVE ANTICIPATED REVENUE GROWTH IF WE ARE NOT SELECTED AS VENDOR OF CHOICE FOR NEW OR EXPANDED FABRICATION FACILITIES AND IF OUR SYSTEMS AND PRODUCTS DO NOT ACHIEVE BROADER MARKET ACCEPTANCE Because semiconductor manufacturers must make a substantial investment to install and integrate capital equipment into a semiconductor fabrication facility, these manufacturers will tend to choose semiconductor equipment manufacturers based on established relationships, product compatibility and proven financial performance. 6 Once a semiconductor manufacturer selects a particular vendor's capital equipment, the manufacturer generally relies for a significant period of time upon equipment from this vendor of choice for the specific production line application. To do otherwise creates risk for the manufacturer because the manufacture of a semiconductor requires many process steps and a fabrication facility will contain many different types of machines that must work cohesively to produce products that meet the customers' specifications. If any piece of equipment fails to perform as expected, the customer could incur significant costs related to defective products, production line downtime, or low production yields. Since most new fabrication facilities are similar to existing ones, semiconductor manufacturers tend to continue using equipment that has a proven track record. Based on our experience with major customers like Samsung, we have observed that once a particular piece of equipment is selected from a vendor, the customer is likely to continue purchasing that same piece of equipment from the vendor for similar applications in the future. Our customer list, though limited, has expanded in recent months. Yet our broadening market share remains at risk to choices made by customers that continue to be influenced by pre-existing installed bases by competing vendors. A semiconductor manufacturer frequently will attempt to consolidate its other capital equipment requirements with the same vendor. Accordingly, we may face narrow windows of opportunity to be selected as the "vendor of choice" by potential new customers. It may be difficult for us to sell to a particular customer for a significant period of time once that customer selects a competitor's product, and we may not be successful in obtaining broader acceptance of our systems and technology. If we are not able to achieve broader market acceptance of our systems and technology, we may be unable to grow our business and our operating results and financial condition will be harmed. OUR LENGTHY SALES CYCLE INCREASES OUR COSTS AND REDUCES THE PREDICTABILITY OF OUR REVENUE Sales of our systems depend upon the decision of a prospective customer to increase manufacturing capacity. That decision typically involves a significant capital commitment by our customers. Accordingly, the purchase of our systems typically involves time-consuming internal procedures associated with the evaluation, testing, implementation and introduction of new technologies into our customers' manufacturing facilities. For many potential customers, an evaluation as to whether new semiconductor manufacturing equipment is needed typically occurs infrequently. Following an evaluation by the customer as to whether our systems meet its qualification criteria, we have experienced in the past and expect to experience in the future delays in finalizing system sales while the customer evaluates and receives approval for the purchase of our systems and constructs a new facility or expands an existing facility. Due to these factors, our systems typically have a lengthy sales cycle during which we may expend substantial funds and management effort. The time between our first contact with a customer and the customer placing its first order typically lasts from nine to twelve months and is often longer. This lengthy sales cycle makes it difficult to accurately forecast future sales and may cause our quarterly and annual revenue and operating results to fluctuate significantly from period to period. If anticipated sales from a particular customer are not realized in a particular period due to this lengthy sales cycle, our operating results may be adversely affected for that period. OUR INTELLECTUAL PROPERTY IS IMPORTANT TO US AND WE RISK LOSS OF A VALUABLE ASSET, REDUCED MARKET SHARE AND LITIGATION EXPENSES IF WE CANNOT ADEQUATELY PROTECT IT. Our success depends in part on our proprietary technology. There can be no assurance that we will be able to protect our technology or that competitors will not be able to develop similar technology independently. We currently have a number of United States and foreign patents and patent applications. On 7 August 1, 2001, we filed a counterclaim against ASM International N.V., charging ASM with infringing Genus' U.S. Patent 5,294,568, entitled "Method of Selective Etching Native Oxide," and with committing antitrust violations designed to harm the atomic layer deposition market. There can be no assurance that any patents issued to us will not be challenged, invalidated or circumvented or that the rights granted thereunder will provide us with competitive advantages. IF WE ARE FOUND TO INFRINGE THE PATENTS OR INTELLECTUAL PROPERTY OF OTHER PARTIES, OUR ABILITY TO GROW OUR BUSINESS MAY BE SEVERELY LIMITED. From time to time, we may receive notices from third parties alleging infringement of patents or intellectual property rights. It is our policy to respect all parties' legitimate intellectual property rights, and we will defend against such claims or negotiate licenses on commercially reasonable terms where appropriate. However, no assurance can be given that we will be able to negotiate necessary licenses on commercially reasonable terms, or at all, or that any litigation resulting from such claims would not have a material adverse effect on our business and financial results. On June 6, 2001, ASM America, Inc. filed suit against us in the U.S. District Court for the Northern District of California asserting that our atomic layer products infringe claims of U.S. Patent Nos. 6,015,590 and 5,916,365. The complaint sought unspecified monetary damages and equitable relief. On August 1, 2001, we filed our response in the patent infringement case initiated by ASM denying ASM's allegation that Genus infringes patents that ASM claims to have acquired. In our response, we deny ASM's and maintain that ASM's claims based on these patents are improper. On January 11, 2002, we received notification from the U.S. District Court for the Northern District of California that the ASM complaint was amended to include an additional infringement claim of U.S. Patent No. 4,798,165. We are currently formulating a response to this latest claim. We intend to defend our position vigorously. The outcome of any litigation is uncertain, however, and we may not prevail. Should we be found to infringe any of the patents asserted, in addition to potential monetary damages and any injunctive relief granted, we would need either to obtain a license from ASM to commercialize our products or redesign our products so they do not infringe any of these patents. If we were unable to obtain a license or adopt a non-infringing product design, we may not be able to proceed with development, manufacture and sale of our atomic layer products. In this case our business may not develop as planned, and our results could materially suffer. WE ARE DEPENDENT UPON KEY PERSONNEL WHO ARE EMPLOYED AT WILL, WHO WOULD BE DIFFICULT TO REPLACE AND WHOSE LOSS WOULD IMPEDE OUR DEVELOPMENT AND SALES We are highly dependent on key personnel to manage our business, and their knowledge of business, management skills and technical expertise would be difficult to replace. Our success depends upon the efforts and abilities of Dr. William W.R. Elder, our chairman and chief executive officer, Dr. Thomas E. Seidel, our chief technology officer, and other key managerial and technical employees who would be difficult to replace. The loss of Dr. Elder or Dr. Seidel or other key employees could limit or delay our ability to develop new products and adapt existing products to our customers' evolving requirements and would also result in lost sales and diversion of management resources. None of our executive officers are bound by a written employment agreement, and the relationships with our officers are at will. 8 Because of competition for additional qualified personnel, we may not be able to recruit or retain necessary personnel, which could impede development or sales of our products. Our growth depends on our ability to attract and retain qualified, experienced employees. There is substantial competition for experienced engineering, technical, financial, sales and marketing personnel in our industry. In particular, we must attract and retain highly skilled design and process engineers. Competition for such personnel is intense, particularly in the San Francisco Bay Area where we are based. If we are unable to retain our existing key personnel, or attract and retain additional qualified personnel, we may from time to time experience inadequate levels of staffing to develop and market our products and perform services for our customers. As a result, our growth could be limited due to our lack of capacity to develop and market our products to customers, or fail to meet delivery commitments or experience deterioration in service levels or decreased customer satisfaction. OUR FAILURE TO COMPLY WITH ENVIRONMENTAL REGULATIONS COULD RESULT IN SUBSTANTIAL LIABILITY TO US We are subject to a variety of federal, state and local laws, rules and regulations relating to the protection of health and the environment. These include laws, rules and regulations governing the use, storage, discharge, release, treatment and disposal of hazardous chemicals during and after manufacturing, research and development and sales demonstrations. If we fail to comply with present or future regulations, we could be subject to substantial liability for clean up efforts, property damage, personal injury and fines or suspension or cessation of our operations. We use the following regulated gases at our manufacturing facility in Sunnyvale: tungsten hexafluoride, dichlorosilane silicide, silane and nitrogen. We also use regulated liquids such as hydrofluoric acid and sulfuric acid. The city of Sunnyvale, California, imposes high environmental standards to businesses operating within the city. Genus has met the city's stringent requirements and has received an operating license from Sunnyvale. Presently, our compliance record indicates that our methods and practices successfully meet standards. Moving forward, if we fail to continuously maintain high standards to prevent the leakage of any toxins from our facilities into the environment, restrictions on our ability to expand or continue to operate our present locations could be imposed upon us or we could be required to acquire costly remediation equipment or incur other significant expenses. WE DEPEND UPON A LIMITED NUMBER OF SUPPLIERS FOR MANY COMPONENTS AND SUBASSEMBLIES, AND SUPPLY SHORTAGES OR THE LOSS OF THESE SUPPLIERS COULD RESULT IN INCREASED COST OR DELAYS IN THE MANUFACTURE AND SALE OF OUR PRODUCTS Components and sub-assemblies included in our products are obtained from a single supplier or a limited group of suppliers. Disruption or termination of these sources could have an adverse effect on our operations. We believe that alternative sources could be obtained and qualified to supply these products, if necessary. Nevertheless, a prolonged inability to obtain components could have a material adverse effect on our operating results. WE DEPEND UPON SIX INDEPENDENT SALES REPRESENTATIVES FOR THE SALE OF OUR PRODUCTS AND ANY DISRUPTION IN THESE RELATIONSHIPS WOULD ADVERSELY AFFECT US We currently sell and support our thin film products through direct sales and customer support organizations in the U.S., Europe, South Korea and Japan and through six independent sales representatives and distributors in the U.S., Europe, South Korea, Taiwan, China and Malaysia. We do not have any long-term contracts with our sales representatives and distributors. Any disruption or termination of our existing distributor relationships could negatively impact sales and revenue. 9 WE ESTABLISHED A DIRECT SALES ORGANIZATION IN JAPAN AND WE MAY NOT SUCCEED IN EFFECTIVELY PENETRATING THE JAPANESE MARKETPLACE We terminated our relationship with our distributor, Innotech Corp. in Japan in 1998. In 2000, we invested significant resources in Japan by establishing a direct sales organization, Genus-Japan, Inc. Although we continue to invest significant resources in our Japan office and have received orders from two new Japanese customers in 2001, we may not be able to attract new customers in the Japanese semiconductor industry, and as a result, we may fail to yield a profit or return on our investment in Japan. THE PRICE OF OUR COMMON STOCK HAS FLUCTUATED IN THE PAST AND MAY CONTINUE TO FLUCTUATE SIGNIFICANTLY IN THE FUTURE, WHICH MAY LEAD TO LOSSES BY INVESTORS OR TO SECURITIES LITIGATION Our common stock has experienced substantial price volatility, particularly as a result of quarter-to-quarter variations in our, our competitors or our customers' actual or anticipated financial results, our competitors or our customers' announcements of technological innovations, revenue recognition policies, changes in earnings estimates by securities analysts and other events or factors. Also, the stock market has experienced extreme price and volume fluctuations which have affected the market price of many technology companies, in particular, and which have often been unrelated to the operating performance of these companies. These broad market fluctuations, as well as general economic and political conditions in the United States and the countries in which we do business, may adversely effect the market price of our common stock. In the past, securities class action litigation has often been instituted against a company following periods of volatility in the company's stock price. This type of litigation, if filed against us, could result in substantial costs and divert our management's attention and resources. BUSINESS INTERRUPTIONS COULD ADVERSELY AFFECT OUR BUSINESS Our operations are vulnerable to interruption by fire, earthquake, power loss, telecommunications failure and other events beyond our control. A disaster could severely damage our ability to deliver our products to our customers. Our products depend on our ability to maintain and protect our operating equipment and computer systems, which is primarily located in or near our principal headquarters in Sunnyvale, California. Sunnyvale exists near a known earthquake fault zone. Although our facilities are designed to be fault tolerant, the systems are susceptible to damage from fire, floods, earthquakes, power loss, telecommunications failures, and similar events. Although we maintain general business insurance against interruptions such as fires and floods, there can be no assurance that the amount of coverage will be adequate in any particular case. WE ARE OBLIGATED TO ISSUE SHARES OF OUR STOCK UNDER OUTSTANDING OPTIONS AND WARRANTS AND SUCH ISSUANCE MAY DILUTE YOUR PERCENTAGE OWNERSHIP IN GENUS OR CAUSE OUR STOCK PRICE TO DROP. As of January 31, 2002, we have a total of 5,231,431 shares of common stock underlying warrants and outstanding employee stock options. Of the stock options, 1,835,202 shares are currently exercisable. All of the shares underlying the warrants are currently exercisable. There are 580,696 shares of our common stock underlying the warrants issued to the shareholders listed in the table below under the section entitled "Selling Securities Holders." These shares have an exercise price of $3.23. The warrants have terms providing for an adjustment of the number of shares underlying the warrants in the event that we issue new shares at a price lower than the exercise price of the warrants, where we make a distribution of common stock to our shareholders or effect a reclassification. 10 If all of the shares underlying the exercisable options and warrants were exercised and sold in the public market, the value of your current holdings in Genus may decline as a result of dilution to your percentage ownership in Genus or as a result of a reduction in the per share value of our stock resulting from the increase in the number of Genus shares available on the market, if such availability were to exceed the demand for our stock. WE HAVE IMPLEMENTED ANTI-TAKEOVER MEASURES THAT MAY RESULT IN DILUTING YOUR PERCENTAGE OWNERSHIP OF GENUS STOCK Please read the section below entitled "Description of Equity Securities" where we more completely summarize our preferred stock rights agreement, which is our primary anti-takeover device. Pursuant to the agreement, our board of directors has declared a dividend of one right for each share of our common stock that was outstanding as of October 13, 2000. The rights trade with the certificates for the common stock until a person or group acquires beneficial ownership of 15% or more of our common stock. After such an event, we will mail rights certificates to our shareholders and the rights will become transferable apart from the common stock. At that time, each right, other than rights owned by an acquiror or its affiliates, will entitle the holder to acquire, for the exercise price, a number of shares of common stock having a then-current market value of twice the exercise price. In the event that circumstances trigger the transferability and exercisability of rights granted in our preferred stock rights agreement, your current holdings in Genus may decline as a result of dilution to your percentage ownership in Genus or as a result of a reduction in the per share value of our stock resulting from the increase in the number of outstanding shares available. FORWARD-LOOKING STATEMENTS We make forward-looking statements in this prospectus that may not prove to be accurate. This prospectus contains or incorporates forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding, among other items, our business strategy, growth strategy and anticipated trends in our business. We may make additional written or oral forward-looking statements from time to time in filings with the Securities and Exchange Commission or otherwise. When we use the words "believe," "expect," "anticipate," "project" and similar expressions, this should alert you that this is a forward-looking statement. We base these forward-looking statements on our expectations. They are subject to a number of risks and uncertainties that cannot be predicted, quantified or controlled. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Statements in this prospectus, and in documents incorporated into this prospectus, including those set forth above in "Risk Factors," describe factors, among others, that could contribute to or cause these differences. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this prospectus will in fact transpire or prove to be accurate. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this section. PROCEEDS We will not receive any of the proceeds from the sale of the shares by the selling security holders. We have agreed to bear all expenses, other than selling commissions and fees and expenses of counsel and other advisers to the 11 selling security holders, in connection with the registration of the shares being offered. We will indemnify the selling security holders against liabilities under the Securities Act of 1933, as amended. All proceeds from the sale of the shares will be for the account of the selling security holders. See "Selling Security Holders" and "Plan of Distribution." SELLING SECURITY HOLDERS The following table sets forth information with respect to the beneficial ownership by the selling security holders of shares of our common stock. We sold the selling security holders an aggregate of 3,871,330 shares of common stock and warrants to purchase an aggregate of 580,696 shares of common stock in a private placement on January 25, 2002. The purchasers paid us $2.25 per share of common stock. The price was based on a discount to the trailing five-day average closing bid price. The warrants have an exercise price of $3.23 per share. For each $15.75 paid to us in the private placement, purchasers received seven shares of our common stock and approximately one warrant share. The number of shares underlying each warrant is determined by the number of shares purchased. The warrants issued to the purchasers in the private placement are exercisable for $3.23 per share. Each warrant is exercisable to purchase shares of our common stock at any time beginning January 25, 2002 and ending after a term of five years. The warrants include a net exercise provision permitting the holders to pay the exercise price by cancellation of a number of shares with a fair market value equal to the exercise price of the warrants. We may request the holders of the warrants issued to the purchasers in the private placement to exercise them if the closing bid price per share of our common stock is greater than $6.46 for each of the ten trading days immediately preceding the date we give notice to the holders of our decision to effect the exercise. Under the terms of this mandatory exercise provision, a holder can choose not to exercise such holder's warrants, although such holder would then forfeit all rights under the warrants to the extent that such holder fails to exercise within twenty business days of receiving our notice. The warrants issued to the purchasers in the private placement include antidilution provisions under section 5, including provisions that call for adjustments in the number of shares of stock issued upon exercise of the warrants to prevent dilution to the holders of the warrants because of (i) dividends or distributions in common stock; (ii) reclassifications of the common stock; or (iii) the issuance of new stock at less than the exercise price of the warrants. The securities offered by this prospectus consist of the shares of common stock acquired by the selling security holders in connection with the above-mentioned private placement and the shares of common stock issuable to them upon exercise of the warrants issued in that private placement ("Offering Shares"). We entered into a registration rights agreement with the selling security holders in connection with the above-mentioned private placement that requires us to file this registration statement. 12
NUMBER OF OFFERING NUMBER OF OFFERING SHARES SHARES BENEFICIALLY BENEFICIALLY OWNED PRIOR TO THE TOTAL OWNED AFTER THE OFFERING OFFERING OFFERING(3) ------------------------------ SHARES ------------------- Number THAT MAY Number of BE SOLD IN of Warrant Percentage THE NAME Shares Shares (1) OFFERING(2) Number Percentage - ------------------------------------------------ --------- ------- ----------- ----------- ------- ---------- Special Situations Private Equity Fund (4) 270,000 40,500 1.18 310,500 0 * Special Situations Technology Fund (4) 175,000 26,250 * 201,250 0 * James Gerson 57,500 21,500 * 79,000 56,000 * Deephaven Private Placement Trading Ltd . (5) 222,222 33,333 * 255,555 0 * Cranshire Capital, L.P. (6) 222,222 33,333 * 255,555 0 * Halifax Fund, L.P. (7) 444,444 66,666 1.94 511,110 0 * Melanie Capital (8) 41,000 17,000 * 58,000 46,500 * Haff Partners, L.P. (9) 135,803 30,651 * 166,454 126,204 * GRT Capital Partners (10) 50,000 7,500 * 57,500 0 * Willow Creek Capital Partners (11) 222,222 33,333 * 255,555 0 * Willow Creek Offshore Fund (11) 222,222 33,333 * 255,555 0 * Kinesis Investment Ltd. (12) 222,222 33,333 * 255,555 0 * Harvey Gelfenbein 22,000 3,300 * 25,300 0 * Timothy S. O'Toole 23,000 3,450 * 26,450 0 * Proximity Fund, L.P. (13) 105,000 15,750 * 120,750 0 * Proximity Fund International Ltd. (13) 45,000 6,750 * 51,750 0 * Roy R. Neuberger 108,000 42,100 * 150,100 111,000 * Tanner Micro Cap Fund (14) 1,900 285 * 2,185 0 * Milwaukee Foundation Micro Cap Fund (14) 13,800 2,070 * 15,870 0 * Jane Pettit Micro Cap Fund (14) 1,900 285 * 2,185 0 * Edward S. Tallmadege (14) 2,000 300 * 2,300 0 * William Chester Childrens Small Cap Fund (14) 1,600 240 * 1,840 0 * Lyndhurst Associates Micro Cap Fund (14) 28,200 4,230 * 32,430 0 * John J. Frautschi Life Trust Micro Cap Fund (14) 40,700 6,105 * 46,805 0 * 13 Posner Partners Micro Cap Fund (14) 14,400 2,160 * 16,560 0 * First American Investment Fund (14) 774,388 116,158 3.39 890,546 0 * Milwaukee Jewish Federation (15) 10,000 1,500 * 11,500 0 * First Investors Holding Co., Inc. (16) 255,555 38,333 1.12 293,888 0 * Tail Wind Fund Ltd. (17) 333,333 49,999 1.46 383,332 0 * Mangin Family LP (18) 62,800 20,050 * 82,850 65,600 * John P. Rosenthal (19) 178,100 49,237 * 227,337 188,237 * TOTALS 4,306,533 739,034 5,045,567 593,541 ========= ======= ======= __________________________ * Indicates less than 1%. 1 Calculated based on Rule 13d-3(d)(1)(i) of the Exchange Act using 26,282,803 shares of common stock outstanding as of January 31, 2002. In calculating this amount for each holder, we treated as outstanding the number of shares of common stock issuable upon exercise of all of that particular holder's warrants. However, we did not assume the exercise of any other holder's warrants. 2 Assumes full exercise of each of the holder's warrants. 3 Assumes the sale of all shares that may be sold in the offering. 4 MG Advisers, L.L.C. is the general partner of and investment adviser to Special Situations Private Equity Fund, L.P. SST Adviser, L.L.C. is the general partner of and investment advisor to Special Situations Technology Fund, L.P. Austin W. Marxe and David M. Greenhouse are the principal owners of MG and SSTA and are principally responsible for the selection, acquisition and disposition of the portfolio securities by the investment advisers on behalf of their fund. 5 Deephaven Private Placement Trading Ltd. is a private investment fund that is owned by all of its investors and managed by Deephaven Capital Management LLC. Deephaven Capital Management LLC, of which Mr. Colin Smith is the fund manager, has voting and investment control over the shares owned by Deephaven Private Placement Trading Ltd. Deephaven Capital Management LLC is an indirect subsidiary of Knight Trading Group, Inc. 6 Downsview Capital, Inc. is the General Partner of Cranshire Capital, L.P. Mitchell P. Kopin, the President of Downsview Capital, Inc., maintains sole authority, with voting and investment power, over the shares owned by Cranshire Capital, L.P. through Downsview Capital, Inc. 7 The Palladin Group L.P. is the investment advisor to Halifax Fund LP and shares voting and investment power, of the shares benificially owned by Halifax Fund, L.P. 8 Melvin Morse is the beneficial owner, with voting and investment power, of the shares owned by Melanie Capital. 9 Drew Gelfenbein is the President of Gledroy Management Corp., a Delaware Corporation. Gledroy Management Corp. is the General Partner of the Gelfenbein Family Partnership and HAFF Partners, which are organized in the state of Delaware. Drew Gelfenbein has the power to act and vote on behalf of the Gledroy Management Corp and consequently HAFF Partners L.P. 10 GRT Capital Partners L.L.C. is the beneficial owner, with voting and investment power, of the shares owned by GRT Topaz Partners L.P., GRT Topaz Partners L.P. [QP], and GRT Offshore Partners Ltd. 14 11 Willow Creek Capital Management is the beneficial owner, with voting and investment power, of the shares owned by Willow Creek Capital Partners and Willow Creek Offshore Fund. 12 Beacon Capital Management is the beneficial owner, with voting and investment power, of the shares owned by Kinesis Investment Ltd. 13 Proximity Capital L.C.C. is the beneficial owner, with voting and investment power, of the shares owned by Proximity Fund, L.P. and Proximity Fund International Ltd. 14 Joseph A. Frohna, as Fund Manager of Firstar Bank, maintains voting and investment power over the shares owned by Tanner Micro Cap Fund, Milwaukee Foundation Micro Cap Fund, Jane Pettit Micro Cap Fund, Edward S. Tallmadege Residuary Trust, William Chester Childrens' Small Cap Fund, Lyndhurst Associates Micro Cap Fund, John J. Frautschi Life Trust Micro Cap Fund, Posner Partners Micro Cap Fund, and First American Investment Fund. 15 Joseph A. Frohna, as Fund Manager of Firstar Bank, maintains voting and investment power over the shares owned by the Milwaukee Jewish Federation. 16 Cavallo Capital Corp., of which Mr. Avi Vigder is managing director, has voting and investment power over the securities beneficially owned by First Investors Holding Co., Inc. 17 Tail Wind Advisory and Management Ltd. is the beneficial owner, with voting and investment power, of the shares owned by Tail Wind Fund Ltd. 18 Joseph Mangin is the beneficial owner, with voting and investment power, of the shares owned by Mangin Family LP. 19 Includes 5,000 shares of common stock held in a trust of which Mr. Rosenthal is the trustee and 15,200 shares of common stock held in a trading account in which Messrs. Rosenthal and Silverberg each own a 50% interest. Mr. Rosenthal, a Senior Vice President of Burnham Securities, Inc., disclaims beneficial ownership of shares held by, or managed in affiliation with, Burnham Securities, Inc.
We prepared this table based on the information supplied to us by the selling shareholders named in the table. The selling shareholders listed in the above table may have sold or transferred, in transactions exempt from the registration requirements of the Securities Act, some or all of theirshares or warrants since the date on which the information in the above table is presented. Information about the selling shareholders may change over time. In the private placement we further agreed, subject to the exceptions discussed below, that we would not conduct any additional financing until July 16, 2002 without the prior written consent of at least a majority of the selling security holders, and if the selling security holders did so consent, to offer them a right of first refusal to participate in such financing on the same terms. Our agreement does not require us to obtain the consent of the selling security holders or offer them a right of first refusal if we conduct any transaction involving - issuances of securities as consideration in a merger, consolidation or acquisition of assets, or in connection with any strategic partnership, collaboration or joint venture (the primary purpose of which is not to raise capital), or as consideration for our acquisition of a business, product or license, - the issuance of securities pursuant to a widely distributed underwritten public offering, 15 - the issuance of securities upon exercise or conversion of our options, warrants or other convertible securities outstanding on May 14, 2001 or issued in the private placement, - the grant of additional options or warrants, or the issuance of additional securities, under any duly authorized stock option, stock purchase or restricted stock plan for the benefit of our employees, consultants or directors, or - any financing with no equity or equity-linked securities made to us by a financial institution engaged in the business of lending money such as a bank, trust company, insurance company or other institutional lender. No selling security holder has held any position or office or had any other material relationship with Genus or any of our affiliates within the past three years. DESCRIPTION OF EQUITY SECURITIES Our authorized capital stock consists of 50,000,000 shares of common stock, no par value per share, and 1,982,000 shares of preferred stock, no par value per share. As of January 31, 2002, 26,282,803 shares of our common stock were outstanding; no shares of our preferred stock were outstanding. As of January 31, 2002, there were 2,067,221 shares of our common stock underlying warrants and 3,164,210 shares of our common stock underlying outstanding employee stock options. The options include 1,835,202 shares that are currently exercisable and 1,329,008 shares that remain unvested. The holders of our common stock are entitled to one vote per share on all matters to be voted upon by the shareholders, except that upon giving the legally required notice, shareholders may cumulate their votes in the election of directors. The common shareholders are entitled to receive ratably such dividends, if any, as may be declared from time to time by the board of directors out of funds legally available therefor. In the event that we liquidate, dissolve or wind up our operations, the holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of any preferred stock, that may be then outstanding. Our common stock has no preemptive or conversion rights or other subscriptions rights. There are no redemption or sinking fund provisions applicable to our common stock. All outstanding shares of our common stock are fully paid and non-assessable. ANTI-TAKEOVER MEASURES On September 7, 2000, our board of directors declared a dividend of one right for each share of our common stock outstanding as of the close of business on October 13, 2000 and directed the issuance of one right for each share of common stock that would become outstanding thereafter. We entered into a preferred stock rights agreement with ChaseMellon Shareholder Services on September 26, 2000 that sets forth the terms and conditions of such rights. The rights will trade with the certificates for the common stock until a person or group acquires beneficial ownership of 15% or more of our common stock or after a person or group announces a tender or exchange offer which would result in another person or group owning 15% or more of our common stock. After such an event, we will mail rights certificates to our shareholders and the rights will become transferable apart from the common stock. At that time, each right will entitle the holder to purchase for an exercise price of $40.00, a fraction of a share of our preferred stock with economic terms similar to that of one share of our common stock. If an acquiror obtains 15% or more of our common stock, then each right, ---- other than rights owned by an acquiror or its affiliates, will entitle the holder to purchase, for the exercise price, a number of shares of our common stock having a then-current market value of twice the exercise price. If, after 16 an acquiror obtains 15% or more of our common stock, (a) we merge into another entity, (b) an acquiring entity merges into us or (c) we sell more than 50% of our assets or earning power, then each right, other than rights owned by an ---- acquiror or its affiliates, will entitle the holder thereof to purchase, for the exercise price, a number of shares of the acquiror's common stock having a then current market value of twice the exercise price. At any time after the date on which an acquiror obtains 15% or more of our common stock and prior to the acquisition of 50% of our outstanding common stock, a majority of our board of directors may exchange the rights for shares of our common stock at an exchange ratio of one share of common stock per right (subject to adjustment). We may redeem the rights for $0.001 per right at any time on or before the fifth day after public announcement that an acquiror attained beneficial ownership of 15% or more of our common stock. The rights expire on the earliest of (a) October 13, 2010 or (b) exchange or redemption of the rights as described above. The terms of the rights and the rights agreement may be amended in any respect without the consent of the rights holders on or prior to the distribution of the rights; thereafter, the terms of the rights and the rights agreement may be amended without the consent of the rights holders in order to cure any ambiguities or to make changes which do not adversely affect the interests of rights holders. The rights do not have any voting rights. PLAN OF DISTRIBUTION The Selling Security Holders and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their shares of Common Stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The Selling Security Holders may use any one or more of the following methods when selling shares: - ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; - block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; - purchases by a broker-dealer as principal and resale by the broker-dealer for its account; - an exchange distribution in accordance with the rules of the applicable exchange; - privately negotiated transactions; - short sales; - broker-dealers may agree with the Selling Security Holders to sell a specified number of such shares at a stipulated price per share; - a combination of any such methods of sale; and - any other method permitted pursuant to applicable law. 17 The Selling Security Holders may also sell shares under Rule 144 under the Securities Act, if available, rather than under this prospectus. Broker-dealers engaged by the Selling Security Holders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Security Holders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The Selling Security Holders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved. The Selling Security Holders may from time to time pledge or grant a security interest in some or all of the securities owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 amending the list of Selling Security Holders to include the pledgee, transferee or other successors in interest as Selling Security Holders under this prospectus. The Selling Security Holders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. The Selling Security Holders and any broker-dealers or agents that are involved in selling the shares may be deemed to be "underwriters" within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The Selling Security Holders have informed the Company that it does not have any agreement or understanding, directly or indirectly, with any person to distribute the Common Stock. LEGAL MATTERS The validity of our Common Stock offered hereby has been passed upon by Wilson Sonsini Goodrich & Rosati, Professional Corporation, Palo Alto, California. As of the date of this Prospectus, members of Wilson Sonsini Goodrich & Rosati, Professional Corporation, who have represented us in connection with this offering, beneficially own approximately 113,750 shares of the our common stock. Mario M. Rosati, a Director and Secretary of Genus, is a member of Wilson Sonsini Goodrich & Rosati, Professional Corporation. EXPERTS The financial statements incorporated in this prospectus by reference to the Annual Report on Form 10-K/A2 for the year ended December 31, 2000, have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, independent accountants, given on the authority of said firm as experts in auditing and accounting. WHERE YOU CAN FIND MORE INFORMATION We have filed with the Securities and Exchange Commission a registration statement on Form S-3, of which this prospectus is a part, under the Securities Act with respect to the shares of common stock offered hereby. This prospectus does not contain all of the information included in the registration statement. Statements in this prospectus concerning the provisions of any document are not necessarily complete. You should refer to the copies of the documents filed as exhibits to the registration statement and those listed below in the section entitled, Information Incorporated by Reference. Each statement concerning these documents is qualified in its entirety by such reference. We are subject to the informational requirements of the Exchange Act and, accordingly, file reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy statements and other information regarding us. The address of the SEC website is http://www.sec.gov. ------------------ 18 Copies of our reports, proxy statements and other information also may be inspected and copied at the public reference facilities maintained by the SEC at: Judiciary Plaza Room 1024 450 Fifth Street, N.W. Washington, D.C. 20549 Copies of these materials can also be obtained by mail at prescribed rates from the Public Reference Section of the SEC, 450 Fifth Street, N.W., Washington, D.C. 20549 or by calling the SEC at 1-800-SEC-0330. Our reports, proxy statements and other public filings may also be inspected at: The National Association of Securities Dealers 1735 K Street, N.W. Washington, D.C. 20006 INFORMATION INCORPORATED BY REFERENCE The SEC allows us to "incorporate by reference" the information we file with them, which means that we can disclose important information to you in this document by referring you to other filings we have made with the SEC. The information incorporated by reference is considered to be part of this prospectus, and later information filed with the SEC will update and supersede this information. We incorporate by reference the documents listed below and any future filings made with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the completion of the offering covered by this prospectus: (1) Registration Statements on Form 8-A filed with the Commission on August 26, 1988, May 3, 1990 and October 3, 2000. (2) Annual Report on Form 10-K for the fiscal year ended December 31, 2000 filed with the Commission on April 2, 2001, and amendments to the Annual Report on Form 10-K/A and Form 10-K/A2, respectively, for the fiscal year ended December 31, 2000 and filed with the Commission on July 20, 2001 and August 7, 2001, respectively. (3) Proxy Statement filed as of April 30, 2001 in connection with the Annual Meeting of Shareholders held on May 24, 2001. (4) Current reports on Form 8-K filed with the Commission on April 11, 2001, May 23, 2001, August 16, 2001, December 13, 2001, and January 28, 2002. (5) Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2001, June 30, 2001, and September 30, 2001 filed with the Commission on May 15, 2001, August 14, 2001, and November 14, 2001 respectively. (6) Registration Statement on Form S-3/A filed with the Commission on August 16, 2001. 19 We will provide without charge to any person, including any beneficial holder, to whom a copy of this prospectus is delivered, upon the written or oral request of any such person, a copy of any document described above (other than exhibits). Requests for such copies should be directed to Genus, Inc. at our principal offices located at 1139 Karlstad Drive, Sunnyvale, California 94089, telephone (408) 747-7120, attention: Investor Relations. 20 PART II INFORMATION NOT REQUIRED IN PROSPECTUS ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION The following table sets forth the various expenses in connection with the sale and distribution of the securities being registered, other than underwriting discounts and commissions. All of the amounts shown are estimates except the Securities and Exchange Commission registration fee and the Nasdaq National Market listing fee.
Securities and Exchange Commission registration fee $ 1,030.91 Nasdaq National Market listing fee. . . . . . . . . $ 22,500 Legal fees and expenses . . . . . . . . . . . . . . $ 50,000 Accounting fees and expenses. . . . . . . . . . . . $ 25,000 Transfer agent and registrar fees and expenses. . . $ 3,750 Miscellaneous . . . . . . . . . . . . . . . . . . . $ 5,000 ----------- Total. . . . . . . . . . . . . . . . . . . . . $107,280.91 ===========
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS Section 317 of the California General Corporation Law authorizes a court to award, or a corporation's Board of Directors to grant, indemnity to directors and officers who are parties or are threatened to be made parties to any proceeding (with exceptions) by reason of the fact that the person is or was an agent of the corporation, against expenses, judgments, fines, settlements and other amounts actually and reasonably incurred in connection with the proceeding if that person acted in good faith and in a manner the person reasonably believed to be in the best interests of the corporation. This limitation on liability has no effect on a directors' liability (i) for acts or omissions that involve intentional misconduct or a knowing and culpable violation of law, (ii) for acts or omissions that a director believes to be contrary to the best interests of the corporation or its security holders or that involve the absence of good faith on the part of the director, (iii) relating to any transaction from which a director derived an improper personal benefit, (iv) for acts or omissions that show a reckless disregard for the director's duty to the corporation or its security holders in circumstances in which the director was aware, or should have been aware, in the ordinary course of performing a director's duties, of a risk of a serious injury to the corporation or its security holders, (v) for acts or omissions that constitute an unexcused pattern of inattention that amounts to an abdication of the directors' duty to the corporation or its security holders, (vi) under Section 310 of the California General Corporation Law (concerning contracts or transactions between the corporation and a director) or (vii) under Section 316 of the California General Corporation Law (directors' liability for improper dividends, loans and guarantees). The provision does not extend to acts or omissions of a director in his capacity as an officer. Further, the provision has no effect on claims arising under federal or state securities laws and does not affect the availability of injunctions and other equitable remedies available to our security holders for any violation of a director's fiduciary duty to us or our security holders. Although the validity and scope of the legislation underlying the provision have not yet been interpreted to any significant extent by the California courts, the provision may relieve directors of monetary liability to us for grossly negligent conduct, including conduct in situations involving attempted takeovers of Genus. In accordance with Section 317, our Restated Articles of Incorporation, as amended (the "Articles"), limit the liability of a director to Genus or our security holders for monetary damages to the fullest extent permissible under II-1 California law, and authorizes Genus to provide indemnification to it agents (including officers and directors), subject to the limitations set forth above. Our Bylaws further provide for indemnification of corporate agents to the maximum extent permitted by the California General Corporation Law. Pursuant to the authority provided in the Articles, we have entered into indemnification agreements with each of our officers and directors, indemnifying them against potential liabilities that may arise as a result of their service and providing for other protection. We also maintain insurance policies that insure our officers and directors against liabilities arising from their positions. The foregoing summaries are necessarily subject to the complete text of the statute, the Articles, the Bylaws and the agreements referred to above and are qualified in their entirety by reference thereto. Reference is made to the Securities Purchase Agreement incorporated by reference as an exhibit to the Registration Statement for provisions regarding indemnification of our officers, directors and controlling persons against liabilities, including liabilities under the Securities Act.
ITEM 16. EXHIBITS EXHIBIT NUMBER DESCRIPTION OF DOCUMENT - ------- ---------------------------------------------------------------------------------------------------- 4.1* Securities Purchase Agreement between Genus, Inc. and the purchasers named in the Selling Security Holders section above. 4.2* Form of Stock Purchase Warrants between Genus, Inc. and the purchasers named in the Selling Security Holders section above (Exhibit A of the Securities Purchase Agreement). 4.3* Registration Rights Agreement between Genus, Inc. and the purchasers named in the Selling Security Holders section above (Exhibit B of the Securities Purchase Agreement). 4.4* Amendment to Registration Rights Agreement between Genus, Inc. and the purchasers named in the Selling Security Holders section above 4.5* Opinion of Company Counsel 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation. 23.1 Consent of Independent Accountants. 23.2 Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (included in Exhibit 5.1 filed herewith). 24.1 Power of Attorney (see page II-5) - ------------------- * Denotes exhibit has been previously filed as an exhibit to the Form 8-K filed with the SEC on January 28, 2002.
ITEM 17. UNDERTAKINGS 1. The undersigned Registrant hereby undertakes: (a) To file, during any period in which offers or sale are being made, a post-effective amendment to this Registration Statement: 2 (i) to include any prospectus required by Section 10(a)(3) of the Securities Act; (ii) to reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment hereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; (iii) to include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement; provided, however, that the undertakings set forth in paragraph (i) and (ii) above shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed by the Registrant pursuant to Section 13 or 15(d) of the Securities Exchange of 1934 (the "Exchange Act") that are incorporated by reference in this Registration Statement. (b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. (c) To remove from registration by means of a post-effective amendment any of the securities being registered that remain unsold at the termination of the offering. 2. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. 3. Insofar as indemnification of liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described under Item 15 above, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registration of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. 4. The undersigned Registrant hereby undertakes that: (a) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective. 3 (b) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. 4 SIGNATURES Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-3 and has duly caused this amended registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Sunnyvale, State of California, on February 7, 2002. GENUS, INC. By: /s/ Shum Mukherjee ---------------------------- Shum Mukherjee Chief Financial Officer POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Mario M. Rosati and Mark Casillas, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendment to this Registration Statement on Form S-3, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated:
SIGNATURE TITLE DATE - ------------------------- ------------------------------------- ---------------- Chairman of the Board, President and February 7, 2002 /s/ William W.R. Elder Chief Executive Officer (Principal - ------------------------- Executive Officer) (William W.R. Elder) /s/Shum Mukherjee Chief Financial Officer February 7, 2002 - ------------------------- (Shum Mukherjee) /s/ Todd S. Myhre Director February 7, 2002 - ------------------------- (Todd S. Myhre) /s/ Mario M. Rosati Director and Secretary February 7, 2002 - ------------------------- (Mario M. Rosati) /s/ G. Frederick Forsyth Director February 7, 2002 - ------------------------- (G. Frederick Forsyth) /s/ George D. Wells Director February 7, 2002 - ------------------------- (George D. Wells) /s/ Robert J. Richardson Director February 7, 2002 - ------------------------- (Robert J. Richardson)
5
INDEX TO EXHIBITS EXHIBIT DESCRIPTION OF DOCUMENT - ------- ------------------------------------------------------------------------------------------------------ 4.1* Securities Purchase Agreement between Genus, Inc. and the purchasers named in the Selling Security Holders section above. 4.2* Form of Stock Purchase Warrants between Genus, Inc. and the purchasers named in the Selling Securities Holders section above (Exhibit A of the Securities Purchase Agreement). 4.3* Registration Rights Agreement between Genus, Inc. and the purchasers named in the Selling Securities Holders section above (Exhibit B of the Securities Purchase Agreement). 4.4* Amendment to Registration Rights Agreement between Genus, Inc. and the purchasers named in the Selling Securities Holders section above 4.5* Opinion of Company Counsel 5.1 Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation. 23.1 Consent of Independent Accountants. 23.2 Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (included in Exhibit 5.1 filed herewith). 24.1 Power of Attorney (see page II-5)
- ------------------- * Denotes exhibit has been previously filed as an exhibit to the Form 8-K filed with the SEC on January 28, 2002. EX-5.1 3 doc2.txt EXHIBIT 5.1 [Letterhead] February 7, 2002 Genus, Inc. 1139 Karlstad Drive Sunnyvale, California 94089 RE: REGISTRATION STATEMENT ON FORM S-3 Ladies and Gentlemen: We have examined the registration statement on Form S-3 to be filed with the Securities and Exchange Commission in connection with the registration under the Securities Act of 1933, as amended, of a resale offering of 3,871,330 shares of your common stock and 580,696 shares of common stock to be issued upon the exercise of warrants to purchase your common stock. We have examined the proceedings taken in connection with the sale and issuance of the above-referenced shares and warrants. It is our opinion that (i) the shares have been legally and validly issued and are fully paid and non-assessable, and (ii) the warrants have been legally and validly issued, and in accordance with the terms and provisions in the warrants, the common shares issued upon exercise of the warrants will be legally and validly issued, and will be fully paid and non-assessable. We consent to the use of this opinion as an exhibit to the registration statement, and further consent to the use of our name wherever appearing in the registration statement, including the prospectus constituting a part thereof, and any amendment thereto. Very truly yours, WILSON SONSINI GOODRICH & ROSATI Professional Corporation /s/ WILSON SONSINI GOODRICH & ROSATI EX-23.1 4 doc3.txt EXHIBIT 23.1 CONSENT OF INDEPENDENT ACCOUNTANTS We hereby consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated February 12, 2001, except as to the second paragraph of Note 6, which is as of March 28, 2001 relating to the financial statements, which appears in Genus, Inc.'s Annual Report on Form 10-K/A2 for the year ended December 31, 2000. We also consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated February 12, 2001 relating to the financial statement schedule which appears in the Genus Inc. Annual Report on Form 10-K/A2 for the year ended December 31, 2000. We also consent to the reference to us under the heading "Experts" in such Registration Statement. /s/ PricewaterhouseCoopers LLP - -------------------------------- San Jose, California February 6, 2002 -----END PRIVACY-ENHANCED MESSAGE-----